Sanofi exec joins Grunenthal as CSO
Grünenthal has announced that Philip Just Larsen is to join the company chief scientific officer (CSO) and member of the corporate executive board. He will assume leadership of the family-owned German drugmaker’s R&D organization on July 1, 2018
Currently, Dr Larsen – a Danish national - holds the role of global head of diabetes research and translational medicine and CSO at French pharma major Sanofi’s (Euronext: SAN) German Hub in Frankfurt.
Dr Larsen is a senior leader with extensive experience in drug discovery and development including successful transition into the clinic. He is a medical doctor trained in internal medicine and neurology, has been awarded a PhD in neuroscience/endocrinology and held international management positions in R&D at Eli Lilly and Novo Nordisk.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze